key: cord-0724405-xv0jhsj0
authors: Perrone, F.; Piccirillo, M. C.; Ascierto, P. A.; Salvarani, C.; Parrella, R.; Marata, A. M.; Popoli, P.; Ferraris, L.; Marrocco Trischitta, M. M.; Ripamonti, D.; Binda, F.; Bonfanti, P.; Squillace, N.; Castelli, F.; Muiesan, M. L.; Lichtner, M.; Calzetti, C.; Salerno, N. D.; Atripaldi, L.; Cascella, M.; costantini, m.; Dolci, G.; Facciolongo, N. C.; Fraganza, F.; Massari, M.; Montesarchio, V.; Mussini, C.; Negri, E. A.; Botti, G.; Cardone, C.; Gargiulo, P.; Gravina, A.; Schettino, C.; Arenare, L.; Chiodini, P.; Gallo, C.
title: Tocilizumab for patients with COVID-19 pneumonia. The TOCIVID-19 phase 2 trial
date: 2020-06-05
journal: nan
DOI: 10.1101/2020.06.01.20119149
sha: bdede964acaceb3ed6f7bc37e97f9a64d3b3b3d5
doc_id: 724405
cord_uid: xv0jhsj0

Background: Tocilizumab blocks pro-inflammatory activity of interleukin-6 (IL-6) which might be important in the pathogenesis of interstitial pneumonia. Objective: to evaluate efficacy of tocilizumab in COVID-19 pneumonia patients. Design: multicenter single-arm phase 2 trial, powered to detect 10% absolute lethality rate reduction at 14 and 30-days, with 20% and 35% expected rates. A consecutive prospective validation cohort was also evaluated. Setting: 185 Italian public hospitals, during coronavirus breakout. Patients: 1221 patients hospitalized with pneumonia, from March 19th to 24th, 2020. Intervention: tocilizumab 8 mg/kg, intravenously, one or two administrations with 12 hours interval. Measurements: lethality rates at 14 and 30-days; safety according to CTCAE. Results: 301 and 920 cases were available for intention-to-treat (ITT) analysis in phase 2 and validation cohorts. Due to delayed drug availability, 60% of patients received tocilizumab, and with some delays. In phase 2, 67 patients died; lethality rates were 18.4% (97.5%CI: 13.6-24.0, P=0.52) and 22.4% (97.5%CI: 17.2-28.3, P<0.001) at 14 and 30-days. Lower rates (15.6% and 20.0%) were reported in the modified ITT including only treated patients (mITT). Lethality rates in the validation cohort were smaller than in phase 2, at 14 and 30 days and in ITT and mITT populations. Multivariable logistic regression model suggests tocilizumab be more effective in patients not requiring mechanical respiratory support at baseline. No relevant signal of specific drug toxicity was reported, many severe adverse events being disease-related. Limitations: single-arm design. In addition, delayed availability of the drug induced indication bias and immortal time bias. Conclusion: Tocilizumab reduced lethality rate at 30 but not at 14-days, compared with the expectations, without significant toxicity. Efficacy was more evident among patients not requiring mechanical respiratory support.

Pneumonia is the most frequent and serious complication of COVID-19, due to excessive host immune response causing an acute respiratory distress syndrome. (1) (2) (3) (4) (5) Interleukin 6 (IL-6) is a pro-inflammatory cytokine implicated in several rheumatic diseases and in the so-called cytokine release syndrome (CRS). Tocilizumab is a recombinant humanized monoclonal antibody, directed against the IL-6 receptor. It is indicated for treating severe rheumatoid arthritis, systemic juvenile idiopathic polyarthritis and severe cytokine release syndrome (CRS) induced by chimeric antigen receptor T-cells (CAR-T). (6, 7) Chinese researchers treated 21 patients with severe or critical COVID-19 pneumonia with tocilizumab 400 mg iv with efficacy in terms of reduction of oxygen requirement (15/20) , resolution of radiologic lung lesions (19/21), normalization of lymphocyte count (10/19) , and reduction of C-reactive protein levels (16/19) . (8) These results prompted a randomized trial (tocilizumab vs control, ChiCTR2000029765) including 188 patients, expected to reach the planned accrual by mid-May 2020.

Therefore, to describe efficacy of tocilizumab while controlling the highly increasing offlabel use of the drug, we launched the TOCIVID-19 study, on March 19 th , 2020 during the ascending phase of the Italian breakout.

According to a specific Italian law, TOCIVID-19 was approved for all Italian centers by the National Ethical Committee at the Lazzaro Spallanzani Institute on March 18 th , 2020; two amendments followed on March 24 th , 2020 and April 28 th , 2020. Database was frozen on May 4 th , 2020. (9) Study design TOCIVID-19 is an academic, no-profit, multicenter, open-label trial including a single-arm phase 2 study, and a companion cohort study.

Sample size for the phase 2 study was initially calculated using 1-month lethality rate as the primary endpoint; based on March 10 th daily report on Italian breakout, 1-month mortality for the eligible population was estimated around 15%; 330 patients were planned to test the alternative hypothesis that tocilizumab may halve lethality rate (from 15% to 7.5%), with 99% power and 5% bilateral alpha error.

The March 28 th amendment, increased the number of patients to be registered to 400, to contrast possible ineligibility after registration, and introduced the companion cohort study of subjects eligible for phase 2 but exceeding the planned sample size, prospectively 4 registered between March 20 th and March 24 th , 2020, to possibly corroborate phase 2 findings.

The April 28 th amendment introduced 14-days lethality rate as co-primary endpoint and redefined the expected lethality rates (null-hypotheses) at 14 and 30-days at 20% and 35%, respectively, thanks to data received from the Italian National Institute of Health. (10) Both changes were introduced blind to efficacy data and in agreement with the Independent Data Monitoring Committee (IDMC). The planned sample size remained unchanged since it still allowed 99% and 95% power to recognize 10% absolute reduction at 14 and 30-days, respectively, with a significant level of 2.5% for each co-primary endpoint.

Patients were eligible if they had SARS-CoV-2 diagnosis done with real-time PCR and were hospitalized due to clinical/instrumental signs of pneumonia. Patients with oxygen saturation at rest in ambient air ≤93% or requiring oxygen support or mechanical ventilation either non-invasive or invasive (intubated less than 24 hours before registration) were eligible.

There was no limitation based on age and gender. Patients were not eligible in case of known hypersensitivity to tocilizumab, known active infections or other clinical conditions contraindicating tocilizumab that could not be treated or solved according to the judgment of the clinician, ALT/AST> 5 times the upper limit of the normality, neutrophils count <500/mmc, platelets <50.000/mmc, bowel diverticulitis or perforation.

Informed consent for participation in the study could be oral if a written consent was unfeasible. However if patients lack capacity to consent due to disease severity, and an authorized representative was not immediately available, treatment could be administered by the treating physician on her/his own responsibility. Consent to remain in the research had to be sought at the earliest opportunity.

According to study design, five populations are defined: (a) intention to treat (ITT) phase 2, defined as all patients enrolled in the phase 2 study; (b) modified ITT (mITT) phase 2, defined as all patients of the ITT phase 2 population who received at least one dose of the study drug; (c) ITT validation population, defined as all patients consecutively and prospectively registered from March 20 th to March 24 th who were potentially eligible for the phase 2 study but exceeded the planned sample size; (d) mITT validation population, defined as all patients of the ITT validation population who received at least one dose of the study drug; (e) safety population, defined as (b) plus (d).

The primary aim of the study was to estimate lethality rates at 14 and 30-days in the ITT phase 2 population. In this paper the same efficacy outcomes are reported for the other ITT and mITT populations. Description of adverse events in the safety population was a 5 key secondary endpoint. Other secondary efficacy endpoints, according to the protocol, will be reported in the future.

Tocilizumab was administered at the dose of 8 mg/kg up to a maximum of 800 mg per dose. Such dose is the same approved by FDA for the treatment of CRS following CAR-T therapy. (6) A second administration of tocilizumab (same dose) was allowed 12 hours after the first if respiratory function had not recovered, at discretion of the Investigator. Tocilizumab was supplied at no cost by Roche Italy. Due to delayed availability of the drug and the rapidly increasing request, a variable delay between the date of patient registration and drug availability at the clinical center occurred. There was no contraindication for concomitant treatment of respiratory impairment; also, concomitant experimental antiviral treatment was allowed.

All adverse events recorded from time of signature of informed consent, throughout the treatment and observation period up to 30-days following registration, had to be reported in the adverse event case report form, graded according to the corresponding CTCAE term (Version 5.0). Causality was assessed by the investigators only when reporting a Serious Adverse Event (SAE). CTCAE coded adverse events are reported for each category and term as the worst grade suffered by patients through the whole period of observation after treatment administration.

Statistical analysis is detailed in the Statistical Analysis plan for primary and secondary endpoints. (10) Briefly, differences between groups of baseline characteristics, collected at the time of registration, are assessed for categorical variables using χ² test and for continuous variables using Wilcoxon rank-sum test. Patients discharged to home or lowintensity care setting are considered alive at the end-date of the follow-up period of 30days. Exact 97.5% Clopper-Pearson confidence intervals (CI) are calculated for the proportions of death at 14 and 30-days. Pre-specified null hypotheses at days 14 and 30 are tested by a two-sided binomial test with alpha level equal to 0.025. Efficacy outcomes (with exact 95% CI) are described in baseline subgroups defined by demographics and clinical variables and compared with exact chi square test.

The effect of treatment on the primary endpoints was further assessed by mean of a multivariable logistic regression model on the two populations combined. Age (≤60, 61-70, >70), gender, type of respiratory support (oxygen, non-invasive mechanical ventilation [NIMV] , invasive mechanical ventilation [IMV]), PAO2/FIO2 ratio (≤100, 101-200, >200, missing/not evaluated), population (phase 2 or validation) and geographical area (Lombardia, Veneto, Emilia-Romagna, other Northern regions, Center, South and Islands) were entered as covariates. The interaction effects between treatment and the other covariates were tested one at a time by Wald test. Patients who received the drug four or more days after registration were excluded from multivariable analysis to rule out the immortal time bias expected with these subjects. Difference in the lethality rate between 6 treated and untreated patients was calculated within specific subgroups and 95% CI was calculated according to the method of Agresti and Caffo. (11) Analysis is carried out using Stata version 14.0 (Stata Corp. College Station, TX, USA) and R version 3.6.1 (R Foundation for Statistical Computing, Vienna, Austria).

The study was sponsored by the National Cancer Institute of Naples and coordinated through the web-based platform of the Clinical Trial Unit. The IDMC was appointed on April 9 th , 2020, including Aldo Maggioni (chief), Paolo Bruzzi, Antonio Pesenti, Valter Torri, and Giuseppe Traversa. Five IDMC meetings were arranged between April 10 th , 2020 and May 12 th , 2020.

No specific funding was available for this study. Tocilizumab was provided by the pharmaceutical company (Roche) free of charge. The National Cancer Institute of Naples was the sponsor of the study and had full property of data and full access to them and final responsibility for the decision to submit for publication.

From March 19 th to 24 th , 2020,185 centers prospectively registered 1685 patients eligible for the present analyses ( Figure 1 ); 13 cases were duplicated or withdrew consent, 399 patients remained in the phase 2 cohort and 1273 in the validation one. In both cohorts, in agreement with IDMC, we removed from analysis all patients recruited from uncooperative centers (i.e. those providing information on baseline characteristics and treatment for less than 25% of the enrolled patients). Therefore, ITT populations include 301 patients in the phase 2 and 920 in the validation cohort. In the phase 2 population, 21 patients found ineligible a posteriori (12 intubated more than 24 hours before registration, 7 registered after being already treated, 2 with both violations) remained in the ITT cohort.

Phase 2 and validation cohorts differ for geographical distribution of centers ( Figure A1 ) and severity of the respiratory disease, with a higher percentage of patients undergoing invasive mechanical ventilation and with a worse profile of PaO2/FiO2 in the phase 2 cohort. Other baseline characteristics are summarized in Table 1 and Tables A1 to A3.

Due to delayed drug availability, treatment was given to only 59.8% of patients, in phase 2, and 59.5% in the validation cohort. Median delay to treatment administration was 2 days in phase 2 and one day in the validation cohort. In both cohorts, 23% of treated patients received tocilizumab after 4 or more days from registration. The most frequent reason for not giving the drug (once it was available) was clinical improvement (Table A4 ). In both 7 cohorts, patients with worse respiratory function were preferentially treated, as shown by the distribution of PaO2/FiO2 ratio and of type of respiratory support, leading to substantial differences in characteristics of the untreated subjects of the two cohorts. In the phase 2 cohort younger patients were also preferentially treated ( Table 2) .

Overall, 67 (22.3%) and 158 (17.2%) deaths were reported in the ITT phase 2 and ITT validation cohorts. As expected given the above characteristics of patients, prognosis was worse in the phase 2 cohort, both in the ITT and mITT populations mainly because the untreated patients in the phase 2 had higher probability of death with respect to the corresponding untreated patients in the validation cohort ( Figure A3 ).

In the ITT phase 2 population, lethality rate was 18.4% (97.5% CI 13.6-24.0) at at 30-days. The null hypothesis was rejected at 30-days but not at 14-days (P<0.001and P=0.52, respectively). At both time points, lethality rates were lower in the mITT population (15.6% and 20.0%). In the validation cohort, lethality rates were consistently lower than the predefined null hypothesis both at 14 and 30-days in the ITT (11.4% and 18.4%) and mITT (10.9% and 20.0%) populations ( Table 3) .

Lethality rates at 14-days were lower for patients receiving treatment 4 or more days after registration, because of the immortal time bias, that disappeared at 30-days, both in phase 2 and validation cohorts. In phase 2, risk of death was significantly increasing in patients older and with worse PaO2/FiO2 ratio (Figure 2a and Table A5 ). Similar findings were observed in the validation cohort, where prognosis was also significantly worsened in patients needing a more intensive respiratory support and in patients suffering mild or worse hypertension (Figure 2b and Table A5 ). At multivariable analysis no significant interaction was found between the effect of treatment and age, gender, PaO2/FiO2 ratio, geographic location and phase 2 vs validation population (data not shown). On the contrary, a significant interaction was found (Table A6) with required respiratory support, interaction test p-values being equal to 0.02 and 0.045 at 14 and 30 days, respectively. Specifically, treatment significantly reduced mortality only in subjects not requiring mechanical respiratory support within 24 hours from registration, while no effect was observed in patients who required invasive or non-invasive mechanical ventilation. At 14 and 30 days, respectively, OR in the former patients were equal to 0.35 (95% CI 0.18-0.70) and 0.47 (95% CI 0.26-0.87) and absolute reductions equal to 7.7% and 6.2% ( Figure A4 panels A and B) . The analysis also confirmed the negative prognostic effect of older age and low PaO2/FiO2 ratio, and the mortality differences between the two study populations.

Adverse events in 628 of 708 patients receiving treatment are summarized in table A6. At least one grade >0 adverse event was reported in 40.8% of patients. Of note, 68 deaths (10.8%) were categorized within adverse events scale. Causality between such deaths and treatment was described as possible only in one of the 35 cases of respiratory failure. All the other fatal adverse events were reported as unlikely or not related to treatment administration. Seven out of 8 fatal infections were specified as COVID pneumonia. Adverse events that may represent specific side effects of tocilizumab are allergic reactions (3 cases) and ALT or AST increase (reported in 10.5% and 9.1% respectively) that was severe (grade 3 or 4) in around 3% of cases. 8 

The primary analysis of TOCIVID-19 suggests that tocilizumab may reduce lethality at 30days, although its impact at 14-days seems less relevant. Multivariable analysis supports that the treatment is effective in patients not requiring mechanical respiratory support. The adverse event profile does not generate clinically relevant warning, possibly because of the severity of clinical symptoms related to the underlying pathologic condition. These results support performing phase 3 clinical trials to confirm the benefit on mortality. Three ongoing randomized trials are comparing tocilizumab vs placebo (ChiCTR2000029765, NCT04320615, NCT04381936) and another one is comparing immediate vs delayed tocilizumab (NCT04346355).

To our knowledge TOCIVID-19 is the largest study on the effect of tocilizumab and the only one prospectively assessing mortality. Only retrospective or observational data have been reported, with prevalently positive results. (8, (12) (13) (14) (15) (16) However, our study has several limitations that deserve discussion for a better interpretation of findings.

The first limitation is the single-arm study design, which prevents firm conclusions. We are aware of weakness of non-randomized design without a control group, in a new disease setting, where no established a priori estimates are available. However, we think that a randomized controlled trial was unfeasible for many reasons. There was a tremendous pressure to have the drug available, due to a widespread media diffusion of positive expectations and to the increasing number of patients hospitalized for the disease, as confirmed by the massive registration of centers as soon as the study began. Thus, obtaining a proper informed consent to randomization would have been extremely difficult also due to patients' condition and clinical burden. Finally, developing a placebo was impossible, and, at least in principle, the risk of cross-over from the control to the experimental arm within a non-blind study would have been high, reducing the validity of the randomized trial itself.

A critical issue of the single-arm design was the definition of the null hypotheses to be tested, due to lack of suitable information at the start of the study. We actually defined them, blind to any result, based on indirect and partial information from Italian institutions.(10) Although we slightly reduced our estimates following the advice of the IDMC, we cannot yet be sure that our assumptions are unbiased. A recent study, with data on near 43.000 patients coming from three Italian regions, reports higher lethality at 14days (22.0%) and lower at 30-days (27.6%) compared to our null hypotheses; assuming these estimates our results would be slightly worse but still clinically significant at 30days. (17) Further, the case-mix of our populations was affected by geographical distribution and by the strategy of the physicians who registered patients in the trial. This is revealed by the evident prognostic difference between phase 2 and validation cohort, the latter being better than the former. It is also surprising that untreated patients in the validation cohort fared much better than untreated ones in phase 2, owing to a likely selection bias of physicians who preferentially treated subjects with worse clinical conditions, thus leading to caution in the interpretation of findings of the validation cohort. 9 A major issue of our study was the discrepancy between drug availability (notwithstanding the commitment of the pharma company) and the extremely high request due to the rapid recruitment rate. As a consequence, two biases could arise: the indication bias, occurring when patients with worse prognosis were preferentially treated, and the immortal time bias, occurring in patients where treatment was delayed, since only subjects surviving longer could receive the drug. Actually, the latter bias was evident at 14-days, but not at 30-days. To rule out the latter bias, patients who received the drug later than 3 days from registration were removed from the multivariable analysis testing the effect of treatment by confounding or prognostic covariates.

Last, we had many missing data, particularly in the validation cohort, for several reasons: massive involvement and stress of physicians in emergency patient care; paucity or absence of data-managers in participating centers; quarantine imposed to paper charts in some centers; impracticality of peripheral monitoring; lack of training of researchers to the web platform; slow web connections with the study platform due to unexpectedly high information loading volume. In agreement with IDMC, we removed uncooperative centers that provided baseline information for less than 25% of patients, but still we cannot be confident that missing data are at random.

Nevertheless, we think that our study has some strengths. As mentioned above, TOCIVID-19 is the first academic trial promoted in Italy, the largest in terms of centers and patients (being available for the whole Italian territory), and most importantly the only one assessing a hard endpoint like mortality. Moreover, the study implemented a hypothesis driven design in a context where off label use of the drug was increasing. In addition, notwithstanding the above discussed limitations, the internal validation, allowed by a companion prospective cohort, contributed to better interpretation of the results. Further analyses will focus on secondary outcomes (e.g. respiratory outcomes, predictive and prognostic factors, epidemiology insights) and on a larger number of patients.

Dr. Perrone reports grants, personal fees and non-financial support from Bayer; grants and personal fees from Incyte, Astra Zeneca, Pierre Fabre; personal fees from Celgene, Janssen Cilag, Roche, Pfizer, Sandoz, outside the submitted work. Dr. Piccirillo reports grants and personal fees from AstraZeneca; grants from Roche; personal fees from Daichii Sankyo, GSK, MSD; non-financial support from Bayer, outside the submitted work. Dr. Ascierto reports grants and personal fees from BMS, Roche-Genentech, Array; personal fees and other from MSD; personal fees from Novartis, Merck Serono, Pierre Fabre, Incyte, Genmab, NewLink Genetics, Medimmune, AstraZeneca, Syndax, Sun Pharma, Sanofi, Idera, Ultimovacs, Sandoz, Immunocore, 4SC, Alkermes, Italfarmaco, Nektar, Boehringer-Ingelheim, outside the submitted work. Dr. Salvarani reports grants and personal fees from Roche; personal fees from Sanofi-Genzyme, Abbvie, Pfizer, Eli-Lilly, Novartis, outside the submitted work. Dr. Castelli reports grants from Gilead, ViiV, GSK, Janssen, Eiger, Roche, Gilead, outside the submitted work. Dr. Gravina reports non-financial support from Pfizer, outside the submitted work.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 5, 2020. . https://doi.org /10.1101 /10. /2020 Dr. Lichtner reports grants from Gilead; personal fees from Abbvie, Merck, Janseen, Angelini, outside the submitted work. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 5, 2020. . . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 5, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 5, 2020 . . https://doi.org/10.1101 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 5, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 5, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 5, 2020. Figure 1 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 5, 2020 June 5, . . https://doi.org/10.1101 June 5, /2020 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 5, 2020 June 5, . . https://doi.org/10.1101 June 5, /2020 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 5, 2020 . . https://doi.org/10.1101 CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 5, 2020 . . https://doi.org/10.1101 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 5, 2020 . . https://doi.org/10.1101 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 5, 2020 . . https://doi.org/10.1101 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 5, 2020 . . https://doi.org/10.1101 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 5, 2020 . . https://doi.org/10.1101 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 5, 2020 . . https://doi.org/10.1101 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 5, 2020 . . https://doi.org/10.1101 16.7 (10.9-24.0) 19.6 (13.3-27.2) 12.2 (9.2-15.9) 19.7 (15.8-24 .1) ≥4 days from registration 11.9 (4.0-25.6) 21.4 (10.3-36.8) 6.5 (2.8-12.4) 21.0 26. 1 (18.4-34.9) 12.7 (9.5-16.7) 17.0 (13.2-21.4 ) P 0.23 0.47 0.16 0.53

Lombardia 20.1 (13.7-27.9) 23.9 (16.9-32.0) 14.7 (11.1-19) 21.6 (17.2-26.5) Veneto 16.9 (8.8-28.3) 20 (11.1-31.8) 7.5 (1.6-20.4) 19.4 (8.2-36 .0) Emilia 18.9 (8-35.2) 12.8 (7.7-19.4) 22.1 (15.6-29.9 ) Other northern --12.6 (6.5-21.5) 14.3 (7.6-23.6 ) Centre 20.8 (7.1-42.2) 6.4 (2.6-12.8) 12.1 (6.6-19.9 (13.6-23.8) 22.9 (17.8-28.8) 11.8 (9.5-14.5) 19. 3 (16.4-22.4 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 5, 2020 . . https://doi.org/10.1101 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 5, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 5, 2020 . . https://doi.org/10.1101 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 5, 2020 . . https://doi.org/10.1101 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 5, 2020 . . https://doi.org/10.1101 

Severe Covid-19

Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region

Clinical Characteristics of Coronavirus Disease 2019 in China

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

A Novel Coronavirus from Patients with Pneumonia in China

FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome

Tocilizumab: A Review in Rheumatoid Arthritis

Effective treatment of severe COVID-19 patients with tocilizumab

Multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia

A phase 2, open label, multicenter, single arm study of tocilizumabon the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia (TOCIVID-19 trial): Statistical Analysis Plan

Simple and Effective Confidence Intervals for Proportions and Differences of Proportions Result from Adding Two Successes and Two Failures

Tocilizumab for the treatment of severe coronavirus disease 2019

Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia

Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE). Microorganisms

Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients

Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia

Survival of hospitalized COVID-19 patients in Northern Italy: a population-based cohort study by the ITA-COVID19

Dario Galante

Stefania Artiol

Andrea Doria, Andrea Vianello

Covid Hospital -Piacenza-Castel

Tamanini Silvia  AO per l'Emergenza Cannizzaro -Catania: Carmelo Iacobello

Bellone Andrea

Napoli -Clinical Trials Unit: Valentina Barbato

Chiara Iommelli

Giusy Giannandrea.  Ospedale Maggiore

Napoli -Clinical Trials Unit: Antonia Del Giudice.  IRCCS Policlinico

only)  Nuovo Ospedale Garibaldi Nesima -Catania: Bruno Cacopardo, Andrea Marino, Alessio Pampaloni

Enzo Castenetto  Presidi Ospedalieri Riuniti ASL.6 Ciriè -Torino: Giuseppe Roberti

 Other TOCIVID-19 Study Coordinators (centres enrolling patients after March 24, 2020 only)  Ospedale degli Infermi